Skip to main content

Universe Pharmaceuticals INC

corporate_fare Company Profile

Universe Pharmaceuticals INC

UPC·NASDAQ·Life Sciences·CIK 0001809616

Universe Pharmaceuticals INC manufactures, markets, distributes, and sells traditional Chinese medicine derivative products in China. The company's products address common chronic health conditions in the elderly, focusing on physical wellness and longevity, and also include cold and flu medications. Key products include guben yanling, shenrong weisheng, and quanlu pill; yangxue danggui and qiangli pipa syrup; wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule. Additionally, Universe Pharmaceuticals INC distributes and sells third-party products such as biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. The company serves pharmaceutical companies, hospitals, clinics, and drugstore chains. Founded in 1998, Universe Pharmaceuticals INC is headquartered in Ji'An, China, and operates as a subsidiary of Sununion Holding Group Limited.

Universe Pharmaceuticals INC (NASDAQ:UPC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for UPC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-29, rated 8/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for UPC spans F-3, 6-K, SCHEDULE 13D, 20-F.

Recent high-impact activity:

  • Universe Pharmaceuticals Files $200M Shelf and Registers 87% of Outstanding Shares for Resale
  • Universe Pharmaceuticals Seeks Shareholder Approval for 1-for-10 Reverse Split to Regain Nasdaq Compliance
  • Universe Pharmaceuticals closes $10.75M Best Praise acquisition, issuing 4.38M shares
  • Universe Pharma Posts $9M Revenue, $1.6M Loss; Unveils $10.75M All-Stock Deal
  • Universe Pharmaceuticals to Acquire Best Praise for $10.75M in Stock, Causing Over 1000% Dilution

Financial Snapshot

Fiscal year ended September 30, 2025
Revenue
$17.86B
Net Income
-$3.67B
Diluted EPS
-$8.06
Op. Cash Flow
-$5.05B
Free Cash Flow
-$5.32B
Gross Profit
$6.3B
Operating Income
-$2.92B
Cash & Equivalents
$33.59B
Total Debt
$2.11B
Debt / Equity
0.04×
Net Margin
-20.6%
Shares Outstanding
563.34K sh
Source: 20-F · filed 2026-01-29 · accession 0001213900-26-009000

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 41,937 shares in UPC as of the October 30, 2026 settlement, a 38.4% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 33.9% of UPC volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)41,937 shares as of October 30, 2026
Change vs prior period▲ 38.4%
Days to cover1.00 at avg daily volume of 291,429
Daily short volume (FINRA facilities)33.9% of 18,695 shares on November 20, 2026
5-day average short volume33.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for UPC, detected from its recent SEC filings.

1 shelf registration

$200M Universal Shelf Registered · 87% of Outstanding Shares Registered for Resale

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

UPC files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with U →
$1.2 +11.11% today
52-week range · as of 2026-09-29 $1.2 – $17.96
Market cap
$5.43M
Volume
50.9K (0.4× avg)
3-mo avg 130.7K
Live data · 2026-11-22 01:28 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed UPC - Latest Insights

UPC
Sep 29, 2026, 4:11 PM EDT
Filing Type: F-3
Importance Score:
8
Price at Filing: $4.52
Real-time Price: $1.20 info
Change: -$3.32 (-73%) info
Market Cap: $5.426M info
UPC
Sep 01, 2026, 5:25 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.27
Real-time Price: $1.20 info
Change: -$3.07 (-72%) info
Market Cap: $5.426M info
UPC
Jul 31, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.88
Real-time Price: $1.20 info
Change: -$2.68 (-69%) info
Market Cap: $5.426M info
UPC
Jul 29, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.26
Real-time Price: $1.20 info
Change: -$2.05 (-63%) info
Market Cap: $5.426M info
UPC
Jun 26, 2026, 4:06 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $4.46
Real-time Price: $1.20 info
Change: -$3.26 (-73%) info
Market Cap: $5.426M info
UPC
Jun 26, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $3.03
Real-time Price: $1.20 info
Change: -$1.83 (-60%) info
Market Cap: $5.426M info
UPC
May 21, 2026, 4:15 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $2.69
Real-time Price: $1.20 info
Change: -$1.49 (-55%) info
Market Cap: $5.426M info
UPC
May 14, 2026, 4:10 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.68
Real-time Price: $1.20 info
Change: -$1.48 (-55%) info
Market Cap: $5.426M info
UPC
Apr 16, 2026, 4:10 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.25
Real-time Price: $1.20 info
Change: -$2.05 (-63%) info
Market Cap: $5.426M info
UPC
Feb 11, 2026, 4:06 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.62
Real-time Price: $1.20 info
Change: -$2.42 (-67%) info
Market Cap: $5.426M info
UPC
Jan 28, 2026, 7:34 PM EST
Filing Type: 20-F
Importance Score:
9
Price at Filing: $4.22
Real-time Price: $1.20 info
Change: -$3.02 (-72%) info
Market Cap: $5.426M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets